Co-enzyme Q10 dietary supplement

Details Co-enzyme Q10 dietary supplement Co-enzyme Q10 dietary supplement

2001-12-12

2003-11-25

Lilling, Herbert J. (Department: 1651)

Drug, bio-affecting and body treating compositions

Plant material or plant extract of undetermined constitution...

Containing or obtained from leguminosae

C424S725000, C424S773000, C424S774000, C424S777000, C514S456000, C514S458000

Reexamination Certificate

active

06652891

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to a method and composition for providing a Coenzyme Q10 product in liquid form as a dietary supplement and/or therapeutic supplement.
BACKGROUND OF THE INVENTION
The uses of coenzyme Q10 as a dietary supplement are manifold and well documented in the scientific literature. Also known as ubidecarenone, it is an antioxidant that plays a critical role in cellular mitochondrial generation of energy, stimulates the immune system, increases circulation and strengthens the cardiovascular system. Deficiencies in coenzyme Q10 have been linked to several debilitating diseases. Current research, and clinical trials around the world are substantiating these and further claims, including periodontal disease, diabetes, asthma, allergies and other respiratory diseases, mental and psychological diseases, cancer, Alzheimer's disease, multiple sclerosis, muscular dystrophy, male impotency and diabetes. It is also being used to reduce side effects of cancer chemotherapy and the treatment of degenerative heart diseases.
Coenzyme Q10 is a class of physiological substances occurring as component factors of the mitochondrial electron transfer system within the biological cell. Coenzyme Q10 acts directly as an electron carrier in oxidative phosphorylation reactions, through metabolic pathways, particularly aerobic pathways, to produce ATP and hence energy. It seems that the demand for coenzyme Q10 is increased in normal subjects in the state of physical fatigue and patients with cardiovascular disease, chronic debilitating disease or on prolonged pharmacotherapy. As a result it may be a sound therapeutic choice to administer coenzyme Q10 to patients suffering from such problems.
In order for coenzyme Q10 to provide its therapeutic effect, the concentration of coenzyme Q10 must increase within the patient's cells. As a result, absorption into the blood stream as well as into the cells themselves is critical. Since coenzyme Q10 is only very sparingly soluble in aqueous solutions, in its natural solid form it is not very soluble in the aqueous gastric juices.
The amount of coenzyme Q10 in the body drops with age. Although it is available in our diet through beef, eggs, fish and organ meats, our assimilation of coenzyme Q10 becomes more difficult with age. As a result, its use as a dietary supplement has increased dramatically in the last decade.
Coenzyme Q10 is not very stable and deteriorates at temperatures above 115° F. It is not water-soluble and is generally provided to the consumer in the form of a hard gelatin capsule containing between 30-60 mg of the powdered coenzyme Q10. Because of this, the absorption of the coenzyme Q10 is limited by the capsule itself and the powdered form of the product. Capsules must be dissolved by the digestive system before their contents can be released into the digestive tract for eventual absorption into the blood stream. If the active ingredients are difficult to get across the membranes into the blood vessels, the absorption will be reduced.
Coenzyme Q10 is a difficult to absorb substance. For this reason, most suppliers recommend that it be taken with fatty foods. However, as a general health recommendation this is not advisable. Advances have been made to improve its absorbability by milling the powder to a very find mesh. The smaller the particle size, the better the absorption.
Thus, it is the object of this invention to provide the consumer with coenzyme Q10 in a novel liquid form, including the oils which have been found to be required for optimal absorption.
SUMMARY OF THE INVENTION
The inventors herein propose a novel liquid composition comprising coenzyme Q10 which optimizes its absorption into the blood stream and into the cells. Thus the novel composition provides an improved therapeutic effect over prior compositions.
The inventors have discovered that a specific oil in water emulsion comprising coenzyme Q10 accomplishes the foregoing objectives. The invention comprises adding coenzyme Q10 to the oil phase of an emulsion. Both the oil and water phases of the emulsion are supplemented with additional ingredients in order to optimize the effectiveness of the overall emulsion. This combination provides a coenzyme Q10 supplement with optimal absorption and therapeutic properties.


REFERENCES:
patent: 4084010 (1978-04-01), Takemoto et al.
patent: 4827062 (1989-05-01), Saeki et al.
patent: 5626868 (1997-05-01), Morancais et al.
patent: 5866158 (1999-02-01), Ribier et al.
patent: 6045826 (2000-04-01), Borowy-Borowski et al.
patent: 6124442 (2000-09-01), Zhou et al.
patent: 6159476 (2000-12-01), Djananov et al.
patent: 6161172 (2000-12-01), Narayan et al.
patent: 6166077 (2000-12-01), De Simone
patent: 6184255 (2001-02-01), Mae et al.
patent: 6203818 (2001-03-01), Vester
patent: 6232346 (2001-05-01), Sole et al.
patent: 6245378 (2001-06-01), Cavazza
patent: 6248363 (2001-06-01), Patel et al.
patent: 6300377 (2001-10-01), Chopra
patent: 6312703 (2001-11-01), Orthoefer
patent: 6372234 (2002-04-01), Deckers et al.
patent: 6441050 (2002-08-01), Chopra
Computer Derwent Abs 1984-265-265868 JP59161313 Sep. 1984.*
Abrahamsson, K., Ericksson, B.O., Holme, E., Jodal, U., Jonsson, A., Lindstedt, S. Pivalic Acid-Induced Carnitine Deficiency and Physical Exercise in Humans. Metabolism: Clinical & Experimental, 45 (12): 1501-7, Dec. 1996.
Anand, I., Chandrashekhan, Y., De Giuli, F., Pasini, E., Mazzoletti, A., Confortini, R., Ferrari, R. Acute and Chronic Effects of Propionyl-L-Carnitine on the Hemodynamics, Exercise Capacity, and Hormones in Patients with Congestive Heart Failure. Cardiovascular Drugs & Therapy. 12 (3): 291-9, Jul. 1998.
Brass, E.P., Hiatt, W.R. The Role of Carnitine and Carnitine Supplementation During Exercise in Man and in Individuals with Special Needs. Journal of the American College of Nutrition, 17 (3) : 207-15, Jun. 1998.
Brevetti, G., Di Lisa, F., Perna, S., Menabo, R., Barbato, R., Martone, V.D., Siliprandi, N. Carnitine-Related Alterations in Patients with Intermittent Claudication: Indication for a Focused Carnitine Therapy, Circulation, 93 (9): 1685-9, May 1996.
Brevetti, G., Fanin, M., De Amicis, V., Carrozzo, R., Di Lello, F., Martone, V.D., Angelini, C. Changes in Skeletal Muscle Histology and Metabolism in Patients Undergoing Exercise Deconditioning: Effect of propionyl-L-carnitine. Muscle & Nerve, 20 (9) :1115-20, Sep. 1997.
Constantin-Teodosiu, D., Howell, S., Greenhaff, P.L. Carnitine Metabolism in Human Muscle Fiber Types During Submaximal Dynamic Exercise. Journal of Applied Physiology, 80 (3):1061-4, Mar. 1996.
Gleim, G.G., Glace, B. Carnitine as an Ergogenic Aid in Health and Disease [editorial; comment]. Journal of the American College of Nutrition, 17 (3): 203-4, Jun. 1998.
Heinonen, O.J. Carnitine and Physical Exercise. Sports Medicine, 22 (2): 109-32, Aug. 1996.
Kaikkonen, J., Kosonen, L., Nyyssonen, K., Porkkala-Sarataho, E., Salonen, R., Korpela, H., Salonen, J.T. Effect of Combined Coenzyme Q10 and d-alpha-tocopheryl Acetate Supplementation on Exercise-Induced Lipid Peroxidation and Muscular Damage: A Placebo-Controlled Double-Blind Study in Marathon Runners.. Free Radical Research, 29 (1): 85-92, Jul. 1998.
Lee, PJ, Harrison, EL, Jones MG, Chalmers RA, Leonard JV, Whipp BJ, “Improvement in exercise tolerance in isovaleric acidaemia with L-carnitine therapy” Journal of Inherited Metabolic Disease. 21(2):136-140, Apr. 1998.
Sole, M.J., Jeejeebhoy, K.N., abstract, The Failing Heart as a Starved Organ: Role of Nutrition in Heart Failure, Mar. 1998, Ottawa, Canada.
Sole, M.J., Keith, M., Ball, A., Kurian, R., Jeejeebhoy, K.N. Cardiovascular Pharmacology (The Failing Myocardium is Nutritionally Deficient). Journal of Cardiac Failure vol. 5 No. 3 Suppl. Sep. 1, 1999.
Sole, M.J., presentation slides, Heart Failure Society of America, 2.sup.nd Annual Meeting, Boca Raton, Florida, “The Fifth Paradigm: A New Look at Heart Failure”, Sep. 1998.
Svesson, M., Malm C., Tonkonogi, M., Ekblom, B., Sjodin, B., Sahlin, K. Effect of Q10 Supplementation on Tissue Q10 Lev

Affiliated with

Also associated with

Rating

Co-enzyme Q10 dietary supplement does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Co-enzyme Q10 dietary supplement, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Co-enzyme Q10 dietary supplement will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3166842